Table 4 Patients’ best response during the treatment period for the full patient cohort and each treatment group

From: A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

Best Response

Total (N = 35)

Treatment Groups

P-value

  

Entinostat + Lapatinib (N = 14)

Entinostat + Lapatinib + Trastuzumab (N = 21)

 

PD

17 (48.6%)

9 (64.3%)

8 (38.1%)

0.1756

No PD

18 (51.4%)

5 (35.7%)

13 (61.9%)

 

No PD

 CR

3 (8.6%)

1 (7.1%)

2 (9.5%)

 

 PR

3 (8.6%)

0 (0%)

3 (14.3%)

 

 SD

12 (34.3%)

4 (28.6%)

8 (38.1%)

 

CB*

7 (20%)

1 (7.1%)

6 (28.6%)

0.2027

No CB

28 (80%)

13 (92.9%)

15 (71.4%)

 

CB*

 CR

3 (8.6%)

1 (7.1%)

2 (9.5%)

 

 PR

3 (8.6%)

0 (0%)

3 (14.3%)

 

 SD ≥ 6 months

1 (2.9%)

0 (0%)

1 (4.8%)

 

Best Response

Total (N = 35)

Treatment Groups

P-value**

  

Entinostat + Lapatinib (N = 14)

Entinostat+ Lapatinib+ Trastuzumab (N = 21)

 

CR

3 (8.6%)

1 (7.1%)

2 (9.5%)

 

PR

3 (8.6%)

0 (0%)

3 (14.3%)

 

SD

12 (34.3%)

4 (28.6%)

8 (38.1%)

 

≥6 months

1 (2.9%)

0 (0%)

1 (4.8%)

 

PD

17 (48.6%)

9 (64.3%)

8 (38.1%)

0.1756

CB*

7 (20%)

1 (7.1%)

6 (28.6%)

0.2027

  1. PD progressive disease, CR complete response, PR partial response, SD stable disease, CB clinical benefit
  2. *CB was defined as CR, PR, or SD ≥ 6 months
  3. **Comparison of presence vs absence of the indicated response in the full patient cohort by student T- test
Back to article page